T3d
Benefits may vary, and results in the general population on CV risk and mortality are still
controversial.
Overall, the results of recent studies have been mixed results. Different study populations,
end points and dosing may account for the lack of clarity. #NephJC
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article š
www.nejm.org/doi/10....
New Trump EO increases fee from $1,000 to $100,000 per year for H1B visas?? Aimed at tech companies hiring cheaper trained people.
However, this is going to be extremely disruptive to residency training programs and hospitals. Hope someone clues him in.
A response to the NYT article about organ donation, from Tom Mone, a former President and Chief Executive Officer of the OneLegacy OPO
sidandt.org/tom-mones-re...
Kidney transplant in patients with C3 glomerulopathy
academic.oup.com/ckj/article/...
My birthday wishlistā¦ š„
I recently attended the Student National Medical Associationās AMEC 2025 conference,where we engaged w/med students/residents to promote the field of nephrology,mentoring opportunities, educational programs & health policy initiatives. It was a pleasure to work with the ASN staff
Oh wowā¦ this has rarely been my practice but very interesting! #NephJC
T1f: #NephJC
3-Year Survival Outcomes
Pts who continued metformin ā„6 months after reaching CKD stage 4 demonstrated significantly higher survival (70.3%; 95% CI, 67.9ā72.8) compared to those who discontinued early (63.4%; 95% CI, 60.5ā66.5)
š”6.9 percentage-point difference (95% CI, 3.2ā10.6)
Worried About the Stock Market? Here's Warren Buffett's Investing Advice for Getting Through It.
Around 62% of U.S. investors are pessimistic about the next six months, according to an April 2025 survey from the American Association of Individual Investors -- the highest figure since March 2009. ...
